New PNH drug iptacopan tested in everyday patients

NCT ID NCT07229235

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 15, 2025 · Last updated May 01, 2026 · Updated 23 times

Summary

This study looks at how well the drug iptacopan works for people with a rare blood disease called PNH. Researchers will track 50 patients in Italy for 12 months to see if their blood health improves and if they need fewer blood transfusions. The goal is to understand the drug's real-world benefits and safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Alessandria, AL, 15121, Italy
Novartis Investigative Site
RECRUITING

Avellino, AV, 83100, Italy
Novartis Investigative Site
RECRUITING

Brescia, BS, 25123, Italy
Novartis Investigative Site
RECRUITING

Florence, FI, 50134, Italy
Novartis Investigative Site
RECRUITING

Palermo, PA, 90146, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00161, Italy
Novartis Investigative Site
RECRUITING

Bassano del Grappa, VI, 36061, Italy

Conditions

Explore the condition pages connected to this study.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)